Literature DB >> 17312127

IL-2/neuroantigen fusion proteins as antigen-specific tolerogens in experimental autoimmune encephalomyelitis (EAE): correlation of T cell-mediated antigen presentation and tolerance induction.

Mark D Mannie1, Barbara A Clayson, Elizabeth J Buskirk, Jarret L DeVine, Jose J Hernandez, Derek J Abbott.   

Abstract

The purpose of this study was to assess whether the Ag-targeting activity of cytokine/neuroantigen (NAg) fusion proteins may be associated with mechanisms of tolerance induction. To assess this question, we expressed fusion proteins comprised of a N-terminal cytokine domain and a C-terminal NAg domain. The cytokine domain comprised either rat IL-2 or IL-4, and the NAg domain comprised the dominant encephalitogenic determinant of the guinea pig myelin basic protein. Subcutaneous administration of IL2NAg (IL-2/NAg fusion protein) into Lewis rats either before or after an encephalitogenic challenge resulted in an attenuated course of experimental autoimmune encephalomyelitis. In contrast, parallel treatment of rats with IL4NAg (IL-4/NAg fusion protein) or NAg lacked tolerogenic activity. In the presence of IL-2R(+) MHC class II(+) T cells, IL2NAg fusion proteins were at least 1,000 times more potent as an Ag than NAg alone. The tolerogenic activity of IL2NAg in vivo and the enhanced potency in vitro were both dependent upon covalent linkage of IL-2 and NAg. IL4NAg also exhibited enhanced antigenic potency. IL4NAg was approximately 100-fold more active than NAg alone in the presence of splenic APC. The enhanced potency of IL4NAg also required covalent linkage of cytokine and NAg and was blocked by soluble IL-4 or by a mAb specific for IL-4. Other control cytokine/NAg fusion proteins did not exhibit a similar enhancement of Ag potency compared with NAg alone. Thus, the IL2NAg and IL4NAg fusion proteins targeted NAg for enhanced presentation by particular subsets of APC. The activities of IL2NAg revealed a potential relationship between NAg targeting to activated T cells, T cell-mediated Ag presentation, and tolerance induction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17312127     DOI: 10.4049/jimmunol.178.5.2835

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells.

Authors:  Mark D Mannie; Kayla B DeOca; Alexander G Bastian; Cody D Moorman
Journal:  Cell Immunol       Date:  2020-07-15       Impact factor: 4.868

2.  IFN-β Facilitates Neuroantigen-Dependent Induction of CD25+ FOXP3+ Regulatory T Cells That Suppress Experimental Autoimmune Encephalomyelitis.

Authors:  Duncheng Wang; Debjani Ghosh; S M Touhidul Islam; Cody D Moorman; Ashton E Thomason; Daniel S Wilkinson; Mark D Mannie
Journal:  J Immunol       Date:  2016-09-12       Impact factor: 5.422

3.  GM-CSF-neuroantigen fusion proteins reverse experimental autoimmune encephalomyelitis and mediate tolerogenic activity in adjuvant-primed environments: association with inflammation-dependent, inhibitory antigen presentation.

Authors:  S M Touhidul Islam; Alan D Curtis; Najla Taslim; Daniel S Wilkinson; Mark D Mannie
Journal:  J Immunol       Date:  2014-07-21       Impact factor: 5.422

4.  A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC.

Authors:  J Lori Blanchfield; Mark D Mannie
Journal:  J Leukoc Biol       Date:  2010-03       Impact factor: 4.962

5.  Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis.

Authors:  Mark D Mannie; J Lori Blanchfield; S M Touhidul Islam; Derek J Abbott
Journal:  Front Immunol       Date:  2012-08-20       Impact factor: 7.561

6.  Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE).

Authors:  Derek J Abbott; J Lori Blanchfield; David A Martinson; Sean C Russell; Najla Taslim; Alan D Curtis; Mark D Mannie
Journal:  BMC Immunol       Date:  2011-12-30       Impact factor: 3.615

Review 7.  Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future.

Authors:  Judith Derdelinckx; Patrick Cras; Zwi N Berneman; Nathalie Cools
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

Review 8.  Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.

Authors:  Cody D Moorman; Sue J Sohn; Hyewon Phee
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

9.  Role of TRIF Small Interference RNA (siRNA) in Chronic Experimental Allergic Encephalomyelitis (EAE).

Authors:  Xichun Wang; Xiufeng Zheng; Chong Ma; Libo Zhao
Journal:  Med Sci Monit       Date:  2015-09-01

10.  A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4+ CD25high FOXP3+ Regulatory T Cells in Myelin-Specific TCR Transgenic Mice Contingent Upon Low-Efficiency T Cell Antigen Receptor Recognition.

Authors:  Cody D Moorman; Alan D Curtis; Alexander G Bastian; Sarah E Elliott; Mark D Mannie
Journal:  Front Immunol       Date:  2019-01-10       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.